Agios is a new company record. Its research profile isn't ready yet.
agios.comCrawled Nov 9, 2026
This site contains educational and scientific information relating to Agios investigational and approved medicines.
The page guides users to search for medical information by selecting a product, therapeutic area, and keywords.
The PYRUKYND website and prescribing information provide details for U.S. patients and healthcare providers.
Agios Chief Medical Officer Sarah Gheuens, M.D., Ph.D., discusses her work on *Just Listen: Voices of PK Deficiency*.
Agios Chief Medical Officer Sarah Gheuens, M.D., Ph.D., discusses her background and clinical development on *Cheat Codes: A Sickle Cell Podcast*.
Agios CEO Jackie Fouse explains the company’s shift to focus on genetically defined diseases in a *Life Science Leader* article.
Agios Head of Patient Advocacy Holly John and former Chief Commercial Officer Darrin Miles appear on *Cheat Codes: A Sickle Cell Podcast*.
Agios is presenting new preclinical and clinical data on mitapivat, the company’s first-in-class pyruvate kinase (PK) activator, along with research from two Agios-supported advisory councils at ASH 2025.
New data on Agios’ first-in-class pyruvate kinase (PK) activator, mitapivat, will be featured in oral and poster presentations highlighting its potential for patients with thalassemia, sickle cell disease, and PK deficiency – serious rare blood disorders with few or no treatment options.
New data on Agios’ mitapivat will be presented at a conference, including Phase 3 results in sickle cell disease.
Agios considers its employees its greatest asset, driving its mission to deliver life-changing treatments.
Agios emphasizes employee well-being as essential to delivering life-changing treatments.
Cecilia joined Agios as chief financial officer in 2022, bringing over 20 years of biopharmaceutical experience, including work in rare diseases.
Ellen became Agios chief people officer in 2022 after leading talent and performance development since 2017.
Mr. Burns serves as Agios chief legal officer, joining in 2016 as senior attorney and head of compliance.
At Agios, leadership means building stronger bonds with colleagues, partners and patient communities and honoring each of their perspectives to make the process of developing life-changing treatments for patients with rare diseases more collaborative, creative and productive.
Agios supports communities affected by rare diseases and connects with those in need of treatment.
Agios’ *Valuing Differences* framework guides its approach to diversity, equity, and inclusion in hiring and operations.
For nearly 15 years, Agios has been committed to furthering the science of cellular metabolism to identify therapies for patients with unmet needs.
88 Sidney Street Cambridge, MA 02139-4169
Agios partners with collaborators to advance treatments for rare diseases by combining expertise and perspectives.
Agios prioritizes patients and scientific rigor, using core strengths to deliver differentiated therapies.
Agios is committed to responsible and transparent external sharing of clinical trial data to promote scientific and medical advancement.
Agios Pharmaceuticals defines privacy principles for handling data in its Data Privacy Framework Policy.
Guidelines for engaging with Agios on social media.
Agios outlines its healthcare compliance program, emphasizing ethical business practices and adherence to laws.
